Abstract This review will focus on findings from the few studies performed to date in humans to examine changes in muscle protein turnover, lean or muscle mass, and physical function following fish oil-derived omega-3 fatty acid treatment. Although considerable gaps in our current knowledge exist, hypertrophic responses (e.g., improvements in the rate of muscle protein synthesis and mTOR signaling during increased amino acid availability and an increase in muscle volume) have been reported in older adults following prolonged (8 to 24 weeks) of omega-3 fatty acid supplementation. There is also accumulating evidence that increased omega-3 fatty acid levels in red blood cells are positively related to strength and measures of physical function. As a result, increased omega-3 fatty acid consumption may prove to be a promising low-cost dietary approach to attenuate or prevent aging-associated declines in muscle mass and function.
Introduction
Aging is associated with a progressive loss of muscle mass and function, a condition frequently termed Bsarcopenia^[1, 2]. The extent of the aging-induced decline in muscle mass and strength has been linked to a greater risk of physical impairment, reduced quality of life, and death [1, 2] with healthcare costs associated with sarcopenia estimated to cost $18.5 billion per year in the USA in 2000 [3] . As a result, development of low-cost therapeutic approaches to combat the deleterious effects of sarcopenia is vitally important to a US population projected to become considerably older over the coming decades [4] . One simple and promising approach may be to increase dietary omega-3 fatty acid consumption, and this review will discuss whether current evidence supports omega-3 fatty acid-induced improvements in muscle protein turnover, mass, and strength in older adults. Areas in need of further study to advance or clarify our understanding of the metabolic effects of omega-3 fatty acids will be highlighted. Finally, while the primary focus of this review will be on responses in older adults, where data only exists in other populations or in animal and cell models these results will be discussed in the context of aging.
Regulation of Muscle Mass
Muscle mass is determined by the balance of the rates of muscle protein synthesis (MPS) and breakdown (MPB) with skeletal muscle protein turnover a tightly controlled process in healthy adults, typically proceeding at a rate of ∼1-2 % per day. Muscle hypertrophy occurs when MPS > MPB with muscle atrophy prevalent when MPB > MPS. Although rates of This article is part of the Topical Collection on Nutrition and Aging MPS and MPB fluctuate throughout the day, the majority of time is spent in the postabsorptive state where the rate of MPB is ∼30-40 % greater than MPS [5, 6] . Periods of muscle protein accretion (i.e., MPS > MPB) therefore only occur intermittently and are typically limited to following protein/mixed meal ingestion where increased circulating amino acid and insulin concentrations stimulate MPS and inhibit MPB. While MPB is sensitive to small increases in insulin concentration, with maximal suppression in MPB occurring at relatively low levels (i.e., ∼30 μU/ mL) [7] , amino acids stimulate MPS in a dose response manner with maximal responses observed following consumption of ∼20 g protein in young, healthy individuals [8] [9] [10] . Consumption of greater amounts of protein is not effective in further stimulating MPS and instead results in oxidation of the excess amino acids [10] . The stimulatory effect of acute hyperaminoacidemia on MPS is short-lived, lasting ∼90 min [11, 12] , after which MPS returns to baseline even in the presence of sustained elevations in plasma amino acid concentration [11, 12] , a phenomenon recently termed the Bmuscle full effect [ 12] . A refractory period of an unknown duration is then required before MPS can again be stimulated by further protein/amino acid administration. Resistance exercise in the postabsorptive state also stimulates MPS, but protein balance remains negative as MPB is also increased, although to a lesser extent than MPS [13, 14] . Net-positive protein balance following exercise therefore only occurs when protein is consumed during the post-exercise period, which results in greater MPS and protein balance compared to protein ingestion or exercise alone [14] [15] [16] . In young, healthy individuals, periods of positive net protein balance are counterbalanced by periods of negative net balance such that muscle mass is typically maintained during early adulthood [17] .
In older adults, a decrease in fasting MPS has been observed by some groups [18] [19] [20] [21] . Aging-induced declines in MPS are, however, likely confined to frail individuals with rates of fasting MPS and MPB reported to be similar in healthy young and older adults [5, 8, 19, 22, 23] . As a result, the current paradigm is for muscle atrophy to occur in the majority of older adults due to blunted responses to previously anabolic stimuli such as protein ingestion/amino acid administration and resistance exercise [24, 25] . There is considerably less information on the effect of aging on MPB compared with MPS; however, it appears that the ability of insulin to suppress MPB is also blunted with aging [26] . As a consequence of aginginduced dysregulation of MPS (and probably also MPB), muscle mass loss occurs at a rate of ∼0.5-1.0 % per year from the fifth or sixth decade onwards [17] with a greater rate of muscle loss observed during times of illness and reduced mobility [27] .
Determinants of Muscle Strength and Function with Aging
The maximum force produced by individual muscle fibers is largely determined by the fiber type (i.e., type II > type I) and the cross-sectional area [28] . As a result, negligible differences in peak power have been reported between muscle fibers from young or older adults in the ex vivo setting when results are normalized to fiber size [28] . This finding differs to in intact humans where the deterioration in muscle function occurs at ∼2-3-fold greater rate than the loss of muscle mass (declines of ∼2-3 vs. ∼0.5-1.0 % per year, respectively) [29, 30] . The reduction in muscle quality (i.e., strength per unit of muscle mass) with aging has been postulated to occur due to changes in the muscle architecture [31] , an increase in intermuscular fat infiltration [32] [33] [34] , greater muscle fibrosis [35, 36] , and reduced neuromuscular activation [37, 38] .
Omega-3 Fatty Acid Intake
Omega-3 fatty acids are polyunsaturated fatty acids that contain a double bond at the third carbon from the methyl end of the chain. Humans, as with all other mammals, are unable to synthesize omega-3 fatty acids de novo, and as a result, they are essential to the diet. In the USA, total omega-3 fatty acid intake is typically between 1.4 and 1.6 g per day [39•, 40, 41] with the majority (∼90 %) consumed as α-linolenic acid (ALA; C18:3n-3), a fatty acid found in many plants, nuts, seeds, and vegetable oils. The ability for humans to elongate and desaturate ALA to produce eicosapentaenoic acid (EPA; C20:5n-3) and docosahexaenoic acid (DHA; C22:6n-3), thought to be the most bioactive omega-3 fatty acids, is extremely limited with <4 % of ALA converted to DHA in men [42] [43] [44] [45] and <10 % converted to DHA in women [46] . Intake of EPA and DHA, which are found in oily fish such as salmon, mackerel, and sardines, is low in the USA with only ∼0.1-0.2 g EPA and DHA typically consumed per day [39•, 40, 41] , a level that is substantially lower than the currently recommended intake of ≈0.5 g per day in healthy individuals [47] and ≈1 g per day for individuals with documented cardiovascular disease [48] .
Increased consumption of fatty fish in the diet or intake of omega-3 fatty acid supplements can markedly increase tissue and cellular omega-3 fatty acid content in a dose response manner [49, 50] . Incorporation of omega-3 fatty acids into lipid membranes occurs very slowly, taking ∼6 months to reach its zenith in red blood cells in healthy men [49] . In addition, there is considerable variability in the omega-3 fatty acid content of different tissues and cells with a ∼50 % higher omega-3 fatty acid content found in erythrocytes than in muscle phospholipids [51] . Nonetheless, a doubling in EPA and DHA content in muscle phospholipids can still be observed when omega-3 fatty acids are supplemented at relatively large doses (i.e., 4 g/day) for 8 weeks [52, 53] .
Positive associations between age and EPA and DHA content in red blood cells and plasma phospholipid have been frequently reported [54] [55] [56] [57] , a finding likely attributable to greater EPA and DHA intake in the older subjects rather than an increased ability to elongate and desaturate ALA in older age [54, 56, 57] . Moreover, the difference in red blood cell and plasma phospholipid EPA and DHA content between young and older adults is considerably smaller than increase in EPA and DHA content typically observed after omega-3 fatty acid supplementation [49, 50, 52, 53] (∼20-25 % difference vs. 200-300 % increase, respectively) [49, 50, [52] [53] [54] [55] [56] .
Muscle Protein Metabolism
There is considerable evidence from animal and in vitro models supporting a stimulatory effect of omega-3 fatty acids on MPS. For example, a greater anabolic response to mixed nutrient feeding was observed following consumption of a DHA-enriched diet for 34 days in growing pigs with no effect on fasting MPS [58] . This response is similar to observed in C2C12 myotubes with EPA treatment having no effect on MPS in the amino acid starved state but inducing a greater MPS response to increased leucine availability [59••] . In both studies, omega-3 fatty acid-induced stimulation of MPS occurred concomitant to greater signaling through the mTOR pathway [58, 59 ••], a feature of omega-3 fatty acid supplementation also reported in growing steer in the fed state [60] .
To determine whether similar responses are observed in humans, we randomized non-obese older adults (aged 65 to 81 years) to supplement with either 4 g/day Lovaza® (GlaxoSmithKline, Research Triangle Park, North Carolina, USA) containing 1.86 g EPA and 1.50 g DHA or an equivalent dose of corn oil (control group) for 8 weeks [52] . Rates of MPS in the postabsorptive state and in response to insulin and amino acid infusion were determined before and after supplementation. In subjects randomized to supplement with corn oil, no change in muscle phospholipid composition, fasting MPS or MPS during amino acid, and insulin infusion was observed. In contrast, omega-3 fatty acid supplementation doubled the EPA and DHA content in muscle phospholipids and resulted in a ∼3-fold greater hyperaminoacidemiahyperinsulinemia-induced increase in MPS (from 0.009 ± 0.005 % · h −1 to 0.031 ± 0.003 %·h −1 above basal values; P < 0.01), which occurred in parallel to ∼50 % greater activation (assessed by degree of phosphorylation) of the p70s6k-mTOR pathway [52] . In a follow-up study, we observed similar responses (i.e., greater MPS and mTOR activation during insulin and amino acid infusion) in younger individuals aged between 25 and 45 years [53] . Specifically, MPS during hyperaminoacidemia-hyperinsulinemia increased from 0.027 ± 0.005 to 0.042 ± 0.005 %·h −1 (P = 0.01) above basal, postabsorptive rates following omega-3 fatty acid supplementation in our younger participants, which coincided with a ∼50 % greater increase in muscle p70s6k and mTOR phosphorylation. Our observations in both young and older adults are therefore remarkably consistent with those reported in animal models and in cell culture [58, 59••, 60] and together suggest that omega-3 fatty acids enhance the MPS response to nutritional stimuli without affecting MPS in the postabsorptive state. Despite convincing evidence that omega-3 fatty acids act through the mTOR pathway [52, 53, 58, 59••, 60] , the mechanism(s) for the increased activation of this pathway is/are presently unknown. Current dogma is that omega-3 fatty acids principally act by reducing the inflammatory state; however, in both our young and older subjects, no change in plasma inflammatory markers (C-reactive protein, tumor necrosis factor-α, and interleukin-6) was observed [52, 53] , presumably due to their low circulating levels prior to supplementation. Nonetheless, we cannot rule out that reductions in local inflammatory signaling (i.e., within skeletal muscle itself) occur, and this possibility requires further study. Alternatively, omega-3 fatty acid supplementation may increase MPS by further stimulating blood flow during hyperaminoacidemia-hyperinsulinemia with improvements in endothelial function frequently reported following omega-3 fatty acid treatment [61] [62] [63] [64] . The ability of insulin to increase blood flow during times of feeding is blunted with aging [65] , which reduces the rate of amino acid delivery to the muscle [66, 67] and is a major contributory factor to the etiology of aging-induced anabolic resistance [66, 68] . Work, to date, has almost entirely focused on the effect of omega-3 fatty acids on changes in MPS with limited information on its effect on MPB and no information on MPB in humans. In vitro studies in C2C12 myotubes [59••] and ex vivo studies in rodents [69] [70] [71] do, however, suggest omega-3 fatty acids inhibit MPB, which, when coupled with an augmented MPS, should improve net protein balance and muscle accretion.
Muscle and Lean Body Mass
Based on muscle protein turnover responses to omega-3 fatty acid supplementation, one would expect a paralleled increase in muscle mass. There is, however, little consensus on the effect of omega-3 fatty acid supplementation on lean body or fat-free mass in the weight stable state in relatively healthy adults. For example, four studies, to date, have reported lean body or fat-free mass to be unchanged following omega-3 fatty acid supplementation [62, [72] [73] [74] with 2 additional studies reporting 1-4 % increases in lean body mass [75, 76] .
Although the discrepant findings may simply be due to the short duration of all of these studies (i.e., 3 to 12 weeks), there is circumstantial evidence that a minimum dose of omega-3 fatty acids (>2 g EPA and DHA per day) may be required before an anabolic response is observed. In support of this notion, when 0.51 to 1.8 g EPA and DHA per day was provided, non-significant results were presented [62, [72] [73] [74] with increases in lean body mass confined to those studies giving 2.4 to 3.0 g EPA and DHA per day [75, 76] . One important limitation of these studies, and by extension the minimum effective dose hypothesis, is that without exception, wholebody lean mass was examined (by dual-energy X-ray absorptiometry, air displacement plethysmography, or bioelectrical impedance analysis) with muscle only contributing ∼50 % to total body lean mass [77] . As a result, small but still physiologically significant changes in muscle mass may go undetected using these whole-body approaches. To overcome this limitation, we recently performed a randomized, controlled double-blind study to examine whether omega-3 fatty acid supplementation affects thigh muscle volume measured by magnetic resonance imaging (MRI) [78••] . Sixty healthy, older adults (aged 60-81 years) consumed either 4 g per day of Lovaza® (GlaxoSmithKline, Research Triangle Park, North Carolina, USA), which contains 1.86 g EPA and 1.50 g DHA, or 4 g of corn oil (control) per day for 6 months with no change in muscle volume found in the control group. In contrast, a 2.2 % (95 % CI 0.3 to 4.2 %) increase in muscle volume above baseline was found in the omega-3 fatty acid group with a treatment effect (i.e., compared to responses in the control group) of 3.6 % (95 % CI 0.2 to 7.0 %). While the omega-3 fatty acid-induced change in muscle volume in this study was smaller than reported following resistance exercise in older adults [79] [80] [81] , the magnitude of the increase was still highly clinically relevant, being equivalent to the amount of muscle lost over a ∼3-year period [1, 2, 30]. Despite these encouraging findings, many questions still remain unanswered. For example, the most effective dose and treatment duration are currently unknown. In addition, it will be important to translate our findings in healthy older adults into more vulnerable populations such as frail and sarcopenic individuals and to study responses in older adults experiencing periods of rapid muscle loss such as during limb immobilization and bed rest.
Strength and Physical Function
Results from cross-sectional studies in older adults have consistently reported positive associations between omega-3 fatty acid intake, greater hand-grip, 1-repetition maximum leg press and isokinetic knee extension strength, and faster chair rise times [82] [83] [84] . To confirm the results from these earlier observational studies, we recently conducted a randomized controlled, double-blind study to examine the effect of omega-3 fatty acid or corn oil (control) supplementation for 6 months on grip strength, 1-repetition maximum strength for several upper and lower exercises, and isometric power in healthy, older adults [78••] . No change in any outcome was observed after 3 months of supplementation; however, treatment effects for hand grip of 2.3 kg (∼6.5 %) and 1-RM muscle strength of 9.1 kg (4.0 %) were apparent at the end of the study with a trend for isometric power to also be improved. Reassuringly, the magnitude of the improvements we observed were consistent with those reported from previous cross-sectional studies [82] and were clinically relevant, equating to prevention of the aging-associated losses of function that occurs over a ∼2-3-year period [29, 30] . These data suggest that omega-3 fatty acid administration improves muscle strength and function in older adults, but there may be a significant latency period before detectable improvements in physical function manifest, a process that could take between ∼3 and 6 months. Greater improvements in lower limb isometric peak torque and chair raising performance following exercise training in older adults have also been observed in subjects supplementing with omega-3 fatty acids compared with exercise training alone [85] . Whether the omega-3 fatty acid-induced improvements in muscle strength and function observed by our group and others [76, 78••, 85] are solely related to gains in muscle mass or are instead influenced by improvements in muscle quality is unclear. However, results from our recent study, where increases in strength following omega-3 fatty acid supplementation were ∼2-fold greater than the gain in muscle volume [78••] , provide at least some circumstantial evidence for an omega-3 fatty acid-induced improvement in muscle quality. Additionally, omega-3 fatty acid supplementation has been reported to improve neuromuscular function [85, 86] and reduce intermuscular fat infiltration [78••] , both of which help determine muscle quality and have been implicated in aginginduced declines in muscle function [32-34, 37, 38] . Changes in other factors that influence muscle quality such as muscle architecture [31] and fibrosis [35, 36] have to the author's knowledge not been examined in response to omega-3 fatty acid treatment.
Conclusions
There is growing evidence that fish-oil derived omega-3 fatty acids stimulate gains in muscle mass in older adults by overcoming aging-induced anabolic resistance. More importantly, omega-3 fatty acid supplementation may also improve strength and muscle function due to a combination of the increased muscle mass and potentially an improvement in muscle quality. Many questions still remain unanswered; however, including whether omega-3 fatty acid-induced improvements in MPS, muscle volume, and muscle function occur in a dose-dependent manner, the latency (if any) and duration of the beneficial responses, whether all populations respond similarly or there is something unique to the healthy individuals that have been studied to date and finally to elucidate the individual roles EPA and DHA play in regulating muscle anabolism and strength in humans. As a result, while omega-3 fatty acids appear to be a promising therapeutic approach to prevent aging-associated declines in muscle mass and function, there is considerable scope for future work to fully elucidate its anabolic potential.
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